Boston Scientific (BSX) stock
NYSE
As of the Nov 13, 2026 close (U.S. Eastern)
- Market cap
- $64.2B
- As of Nov 13, 2026
- P/E
- 18.35x
- Trailing twelve months
- P/B
- 2.51x
- Latest reported equity
- P/S
- 3.05x
- Trailing twelve months
- ROE
- 13.7%
- Trailing twelve months
- Dividend yield
- Not available
- Latest fiscal-year dividends
Multiples use the price as of Nov 13, 2026 and may differ from the current price.
- Market cap
- $64.2B
- As of Nov 13, 2026
- P/E
- 18.35x
- Trailing twelve months
- P/B
- 2.51x
- Latest reported equity
- P/S
- 3.05x
- Trailing twelve months
- ROE
- 13.7%
- Trailing twelve months
- Dividend yield
- Not available
- Latest fiscal-year dividends
Multiples use the price as of Nov 13, 2026 and may differ from the current price.
Compares the share price with the company's earnings, net assets and sales. Check trading status and financial notes separately.
Price date for the multiples · Nov 13, 2026 · Financial period · Trailing twelve months
P/E and P/S use the latest four quarters where available · P/B uses the latest equity · Computed in-house by ChickenStock
P/E
18.35x
P/B
2.51x
P/S
3.05x
Earnings and dividend metrics▾
Earnings
EPS
$2.42
Earnings per share
BPS
$17.69
Book value per share
ROE
13.7%
Return on equity
- EPS — what one share earned over the last four quarters. This company earned $2.42 per share.
- BPS — net assets divided by the number of shares. Each share is backed by $17.69 of net assets.
- ROE — how much the company earned on shareholder equity over a year: 13.7%.
ⓘ What are these valuation metrics?▾
P/E = share price ÷ earnings per share (EPS)
P/B = share price ÷ book value per share (BPS)
P/S = share price ÷ sales per share
P/E shows how many times annual earnings per share the price is; not all earnings are paid to shareholders. P/B compares the price with net assets, and P/S with sales.
Higher or lower is not good or bad by itself. Typical levels differ by industry; read P/B alongside ROE and P/S alongside margins.
ChickenStock computes these from SEC financial filings: net income and revenue are summed over the latest four quarters, and equity is the latest reported balance.
A negative P/E means a net loss. Reference information only, not a recommendation to buy or sell.
Latest earnings
SEC filingsJul–Sep 2026(FY2026 Q3)
Revenue increased 1.4% from the same period a year earlier.
Key reported figures come first. Select one to see the same quarter across three years.
Revenue · same quarter, three years
Year-ago quarter $5.07B+1.4%
$4.21B
Jul–Sep '24
$5.07B
Jul–Sep '25
$5.14B
Jul–Sep '26
The next earnings date has not been confirmed yet.
ⓘ Notes on these figures▾
- Results for Jul–Sep 2026 are from the 10-Q submitted to SEC EDGAR on Nov 2, 2026.
- Earnings per share decreased 21.6% from the same quarter a year earlier.
- Revenue increased 1.4% from the same quarter a year earlier.
- Operating income decreased 21.0% from the same quarter a year earlier.
- Net income decreased 22.9% from the same quarter a year earlier.
Filed Nov 2, 2026 · 10-Q · SEC EDGAR
Reported results are from SEC EDGAR filings. Reference information only, not investment advice.
Insider transactions
Recent Form 4 filings grouped by person, date and transaction type.
- Mahoney Michael FChairman, President & CEO · Nov 4, 2026Gift252,241 shares · $0Avg. price $0
Show 2 price lots
- 102,249 shares × $0$0
- 149,992 shares × $0$0
- O'Sullivan MiriamSVP, Chief HR Officer · Nov 1, 2026Shares withheld for taxes1,872 shares · $79KAvg. price $41.9819,565 shares held after
- O'Sullivan MiriamSVP, Chief HR Officer · Nov 1, 2026Option exercise3,871 shares · $0Avg. price $021,437 shares held after
- O'Connor Padraig AndrewEVP, Global Operations · Sep 2, 2026Shares withheld for taxes567 shares · $27KAvg. price $48.377,892 shares held after
- O'Connor Padraig AndrewEVP, Global Operations · Sep 2, 2026Option exercise1,171 shares · $0Avg. price $08,459 shares held after
- Morano Susan EDirector · Aug 25, 2026Open-market purchase2,040 shares · $100KAvg. price $49.219513,784 shares held after
- Woodworth EmilySVP, Global Controller and CAO · Aug 11, 2026Other2,930 shares · $150KAvg. price $51.192,930 shares held after
- Monson JonathanEVP and CFO · Aug 10, 2026Other9,908 shares · $500KAvg. price $50.469,908 shares held after
- Habiger David CDirector · Aug 5, 2026Open-market purchase2,100 shares · $100KAvg. price $47.58917,160 shares held after
- Habiger David CDirector · Aug 4, 2026Open-market purchase140 shares · $7KAvg. price $48.587915,060 shares held after
- Mahoney Michael FChairman, President & CEO · Aug 3, 2026Open-market purchase186,240 shares · $9.0MAvg. price $48.33231,590,024 shares held after
- Habiger David CDirector · Aug 3, 2026Open-market purchase1,042 shares · $50KAvg. price $48.065514,920 shares held after
- Mahoney Michael FChairman, President & CEO · Aug 3, 2026Other22,119 shares · $1.1MAvg. price $48.4322,119 shares held after
- LUDWIG EDWARD JDirector · Jul 31, 2026Open-market purchase5,000 shares · $227KAvg. price $45.479930,359 shares held after
- Fitzgerald Joseph MichaelEVP & Group Pres, Cardiology · Jul 31, 2026Other64,198 shares · $3.0MAvg. price $46.7364,198 shares held after
Only transactions reported on SEC Form 4 are shown. A sale may follow a pre-arranged 10b5-1 plan, and items such as option exercises or shares withheld for taxes are not open-market trades.
Recent SEC filings
40 filingsRecent filing summaries
Newest first by publication date · may differ from the filing date
- AI summary10-QThe company said a cybersecurity incident identified in August 2026 caused disruptions to global operations, including manufacturing and processing and shipping customer orders, and that it materially impacted its financial results for Q3.Published Nov 2, 2026 · Filed Nov 2, 2026Read the summary →
- AI summary8-KBoston Scientific said net sales for Q3 2026 were $5.138 billion, up 1.5% from the prior-year period on a reported, operational and organic basis. For Q3, GAAP net income attributable to Boston Scientific common stockholders was $582 million, or $0.40 per share.Published Oct 28, 2026 · Filed Oct 28, 2026Read the summary →
- AI summary8-KBoston Scientific announced on October 7, 2026 that Joe Fitzgerald, who currently serves as Executive Vice President and Group President, Cardiovascular, has been promoted to Executive Vice President and Chief Operating Officer, effective January 1, 2027.Published Oct 7, 2026 · Filed Oct 7, 2026Read the summary →
- The company said a cybersecurity incident identified in August 2026 caused disruptions to global operations, including manufacturing and processing and shipping customer orders, and that it materially impacted its financial results for Q3.Read the full analysis →
- Boston Scientific said net sales for Q3 2026 were $5.138 billion, up 1.5% from the prior-year period on a reported, operational and organic basis. For Q3, GAAP net income attributable to Boston Scientific common stockholders was $582 million, or $0.40 per share.Read the full analysis →
- Boston Scientific announced on October 7, 2026 that Joe Fitzgerald, who currently serves as Executive Vice President and Group President, Cardiovascular, has been promoted to Executive Vice President and Chief Operating Officer, effective January 1, 2027.Read the full analysis →
Filings submitted to the U.S. Securities and Exchange Commission (EDGAR). Dates are SEC filing dates (U.S. Eastern). Form and item names are the official SEC titles. The Earnings and Risk tags come directly from form types and item codes; they are not written by AI. Insider ownership reports (Forms 3, 4 and 5) are excluded.
Company overview
Expand ▾
Boston Scientific (BSX) stock information
NYSE
Boston Scientific (BSX) is listed on NYSE. Its market capitalization is about $64.2B. On trailing-twelve-month earnings the P/E ratio is 18.35, and the P/B ratio is 2.51. Return on equity is 13.7%. These figures are computed in-house from official filings and are reference information only.
Boston Scientific — frequently asked questions
- What is the P/E ratio of Boston Scientific (BSX)?
- On a trailing-twelve-month basis, BSX trades at a P/E ratio of 18.35. It is calculated as market capitalization divided by net income attributable to controlling interests, using official filings. Reference information only.
- What is the market capitalization of Boston Scientific?
- BSX has a market capitalization of about $64.2B. The figure moves with the share price and is refreshed each trading day.
- Is this page investment advice?
- No. Every figure on this page is factual reference information compiled from public filings. It is not investment advice, not a price forecast and not a recommendation to buy or sell. Investment decisions rest with the user.
All metrics, scores, and content provided by ChickenStock are reference information derived from market data. They are not investment advice or a solicitation to trade. Investment decisions and their consequences rest with the user.